Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology test… Read more
Shin Nippon Biomedical Laboratories, Ltd. - Asset Resilience Ratio
Shin Nippon Biomedical Laboratories, Ltd. (SBLOF) has an Asset Resilience Ratio of 0.14% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Shin Nippon Biomedical Laboratories, Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Shin Nippon Biomedical Laboratories, Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $120.99 Million | 0.14% |
| Total Liquid Assets | $120.99 Million | 0.14% |
Asset Resilience Insights
- Limited Liquidity: Shin Nippon Biomedical Laboratories, Ltd. maintains only 0.14% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shin Nippon Biomedical Laboratories, Ltd. Industry Peers by Asset Resilience Ratio
Compare Shin Nippon Biomedical Laboratories, Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Shin Nippon Biomedical Laboratories, Ltd. (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Shin Nippon Biomedical Laboratories, Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-03-31 | 0.44% | $336.72 Million | $76.30 Billion | -0.50pp |
| 2022-03-31 | 0.94% | $368.09 Million | $39.31 Billion | +0.79pp |
| 2021-03-31 | 0.15% | $55.77 Million | $36.97 Billion | -- |